Trial Profile
Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DRONE
- 07 Mar 2018 Results (n=27) assessing the dynamics of archived HIV-DNA in CD4+ T-cells subsets in individuals starting successful dolutegravir-based regimen over 48 weeks presented at the 25th Conference on Retroviruses and Opportunistic Infections
- 16 Feb 2017 Results (n=20) presented at the 24th Conference on Retroviruses and Opportunistic Infections
- 03 Mar 2015 New trial record